Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13177436 | 0.86 | MEN1 (0.74) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL23726645 | 0.84 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL21636035 | 0.84 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL2228161 | 0.84 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL2853678 | 0.76 | MEN1 (0.61) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL23727096 | 0.75 | MEN1 (0.58) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL13238689 | 0.74 | MEN1 (0.56) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL13238668 | 0.74 | MEN1 (0.56) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL8288062 | 0.72 | MAPT (0.54) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL13238712 | 0.72 | MEN1 (0.56) | MEN1MAPTCYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3849310-B1 | COMBINATION CANCER THERAPIES BASED ON THE MORTALIN TARGETING COMPOUND SHETA2 AND P53 REACTIVATORS OR CDK4/6 INHIBITORS | UNIV OKLAHOMA (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260002222-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALT CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2026-01-01 | — | — | US | claimed |
| EP-4012713-B1 | SYSTEMS AND METHODS FOR GENERATING, VISUALIZING AND CLASSIFYING MOLECULAR FUNCTIONAL PROFILES | BOSTONGENE CORP (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250325548-A1 | TUMOR SUPPRESSOR P73 TRANSCRIPTIONALLY REGULATES C-FLIP TO IMPEDE ITS PRIMING OF EXTRINSIC APOPTOSIS WHILE AN EXAMPLE SWITCHER COMPOUND CB-7587351 DEGRADES C-FLIP PROTEIN | UNIV BROWN (US) | 2025-10-23 | — | — | US | claimed |
| US-12435380-B2 | Compositions and methods for the diagnosis and treatment of ALT cancer | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-10-07 | — | — | US | claimed |
| US-20240299492-A1 | COMBINATION THERAPIES WITH SIRP ALPHA-BASED CHIMERIC PROTEINS | SHATTUCK LABS, INC. | 2024-09-12 | — | — | US | claimed |
| US-20240158866-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALT CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2024-05-16 | — | — | US | claimed |
| CN-111033631-B | System and method for generating, visualizing and classifying molecular functional spectra | 波士顿基因公司 | 2024-03-12 | — | — | CN | claimed |
| US-11913077-B2 | Compositions and methods for the diagnosis and treatment of ALT cancer | TEXAS TECH UNIVERSITY SYSTEM (US) | 2024-02-27 | — | — | US | claimed |
| EP-1605939-B1 | PHARMACEUTICAL USE OF 1-AZABICYCLO¬ 2.2.2 OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53 | APREA AB (SE) | 2008-10-15 | — | — | EP | claimed |
| US-7348330-B2 | 1-azabicyclo [2,2,2] octan-3-one derivatives | APREA AB (SE) | 2008-03-25 | — | — | US | claimed |
| US-20060276502-A1 | Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53. | APREA AB (SE) | 2006-12-07 | — | — | US | claimed |
| EP-1605939-A1 | PHARMACEUTICAL USE OF 1-AZABICYCLO[ 2.2.2] OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53 | APREA AB (SE) | 2005-12-21 | — | — | EP | claimed |
| US-6921765-B2 | 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors | APREA AB (SE) | 2005-07-26 | — | — | US | claimed |
| US-20050090540-A1 | 1-Azabicyclo [2,2,2] octan-3-one derivatives | APREA AB (SE) | 2005-04-28 | — | — | US | claimed |
| WO-2004084893-A1 | PHARMACEUTICAL USE OF 1-AZABICYCLO[2.2.2]OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53 | APREA AB (SE) | 2004-10-07 | — | — | WO | claimed |
| US-20030166674-A1 | 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors | APREA THERAPEUTICS AB (SE) | 2003-09-04 | — | — | US | claimed |
| EP-1319000-A1 | 1-AZABICYCLO 2.2.2]OCTAN-3-ONE DERIVATIVES AND MALEIMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER TUMORS | Karolinska Innovations AB (SE) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024692-A1 | 1-AZABICYCLO[2.2.2]OCTAN-3-ONE DERIVATIVES AND MALEIMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER TUMORS | KAROLINSKA INNOVATIONS AB (SE) | 2002-03-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090540-A1 | 1-Azabicyclo [2,2,2] octan-3-one derivatives | TP53, ACIN1, BCLAF1 | MEN1 4423/4885MAPT 4055/4885CYP2C9 3877/4885 |
| US-20060276502-A1 | Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53. | TP53, TP53BP1, MITF | MEN1 507/4885MAPT 2020/4885CYP2C9 1266/4885 |
| US-20260002222-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALT CANCER | TERT, POT1, TELO2 | MEN1 908/4885MAPT 442/4885CYP2C9 4503/4885 |
| US-20250325548-A1 | TUMOR SUPPRESSOR P73 TRANSCRIPTIONALLY REGULATES C-FLIP TO IMPEDE ITS PRIMING OF EXTRINSIC APOPTOSIS WHILE AN EXAMPLE SWITCHER COMPOUND CB-7587351 DEGRADES C-FLIP PROTEIN | BCOR, CCAR2, CEBPZ | MEN1 3174/4885MAPT 4116/4885CYP2C9 4518/4885 |
| US-20030166674-A1 | 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors | TP53, BBC3, ERCC2 | MEN1 2436/4885MAPT 3755/4885CYP2C9 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.